25 years of the WHO essential medicines lists: progress and challenges.

Hdl Handle:
http://hdl.handle.net/10144/28005
Title:
25 years of the WHO essential medicines lists: progress and challenges.
Authors:
Laing, R; Waning, B; Gray, A; Ford, N; 't Hoen, E
Journal:
Lancet
Abstract:
The first WHO essential drugs list, published in 1977, was described as a peaceful revolution in international public health. The list helped to establish the principle that some medicines were more useful than others and that essential medicines were often inaccessible to many populations. Since then, the essential medicines list (EML) has increased in size; defining an essential medicine has moved from an experience to an evidence-based process, including criteria such as public-health relevance, efficacy, safety, and cost-effectiveness. High priced medicines such as antiretrovirals are now included. Differences exist between the WHO model EML and national EMLs since countries face varying challenges relating to costs, drug effectiveness, morbidity patterns, and rationality of prescribing. Ensuring equitable access to and rational use of essential medicines has been promoted through WHO's revised drug strategy. This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines.
Affiliation:
Boston University School of Public Health, Boston, MA 02118, USA. richardl@bu.edu <richardl@bu.edu>
Publisher:
Elsevier
Issue Date:
17-May-2003
URI:
http://hdl.handle.net/10144/28005
DOI:
10.1016/S0140-6736(03)13375-2
PubMed ID:
12767751
Language:
en
ISSN:
0140-6736
Appears in Collections:
Health Politics

Full metadata record

DC FieldValue Language
dc.contributor.authorLaing, R-
dc.contributor.authorWaning, B-
dc.contributor.authorGray, A-
dc.contributor.authorFord, N-
dc.contributor.author't Hoen, E-
dc.date.accessioned2008-05-26T10:58:43Z-
dc.date.available2008-05-26T10:58:43Z-
dc.date.issued2003-05-17-
dc.identifier.citation25 years of the WHO essential medicines lists: progress and challenges. 2003, 361 (9370):1723-9 Lanceten
dc.identifier.issn0140-6736-
dc.identifier.pmid12767751-
dc.identifier.doi10.1016/S0140-6736(03)13375-2-
dc.identifier.urihttp://hdl.handle.net/10144/28005-
dc.description.abstractThe first WHO essential drugs list, published in 1977, was described as a peaceful revolution in international public health. The list helped to establish the principle that some medicines were more useful than others and that essential medicines were often inaccessible to many populations. Since then, the essential medicines list (EML) has increased in size; defining an essential medicine has moved from an experience to an evidence-based process, including criteria such as public-health relevance, efficacy, safety, and cost-effectiveness. High priced medicines such as antiretrovirals are now included. Differences exist between the WHO model EML and national EMLs since countries face varying challenges relating to costs, drug effectiveness, morbidity patterns, and rationality of prescribing. Ensuring equitable access to and rational use of essential medicines has been promoted through WHO's revised drug strategy. This approach has required an engagement by WHO on issues such as the effect of international trade agreements on access to essential medicines and research and development to ensure availability of new essential medicines.en
dc.language.isoenen
dc.publisherElsevieren
dc.rightsReproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/[/url] for further relevant comment.en
dc.subject.meshConsumer Advocacyen
dc.subject.meshForecastingen
dc.subject.meshGuidelines as Topicen
dc.subject.meshHealth Care Reformen
dc.subject.meshHealth Services Accessibilityen
dc.subject.meshHistory, 20th Centuryen
dc.subject.meshHistory, 21st Centuryen
dc.subject.meshHumansen
dc.subject.meshIntellectual Propertyen
dc.subject.meshModels, Organizationalen
dc.subject.meshPharmaceutical Preparationsen
dc.subject.meshPolicy Makingen
dc.subject.meshSouth Africaen
dc.subject.meshWorld Health Organizationen
dc.title25 years of the WHO essential medicines lists: progress and challenges.en
dc.contributor.departmentBoston University School of Public Health, Boston, MA 02118, USA. richardl@bu.edu <richardl@bu.edu>en
dc.identifier.journalLanceten

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.